James Surek. [Image courtesy of Valencia Technologies]

詹姆斯·苏雷克。[图片由瓦伦西亚科技提供]

Valencia Technologies

瓦伦西亚科技公司

announced today that it received a strategic investment totaling up to $35 million and appointed a new CEO.

今天宣布获得高达 3500 万美元的战略投资，并任命了新的首席执行官。

The neuromodulation company focused on treating urinary incontinence named James D. Surek as its new CEO. Valencia plans to leverage its new capital and Surek’s commercial leadership experience to fuel the growth of its eCoin system.

专注于治疗尿失禁的神经调节公司任命詹姆斯·D·苏雷克为新任首席执行官。瓦伦西亚计划利用其新资本和苏雷克的商业领导经验，推动其eCoin系统的增长。

eCoin, a coin-sized neurostimulator, is implanted under the skin near the ankle. The implant takes place in a minimally invasive, outpatient procedure utilizing local anesthetic. eCoin automatically delivers periodic stimulation to the tibial nerve twice weekly to reduce episodes of urge urinary incontinence (UUI)..

eCoin是一种硬币大小的神经刺激器，被植入脚踝附近的皮肤下。该植入过程通过使用局部麻醉剂的微创门诊手术完成。eCoin每周自动向胫神经提供两次周期性刺激，以减少急迫性尿失禁（UUI）的发作。

Unlike other stimulation devices, the system streamlines the post-implant experience, according to a news release. Most patients require just one post-implant programming session. It eliminates the need for weekly recharging or patient programmers.

据新闻稿称，与其他刺激设备不同，该系统简化了植入后体验。大多数患者只需一次植入后的编程调试。它消除了每周充电或患者编程的需求。

Surek previously played a role in the commercial success of five medical device companies that executed successful M&A exits. He built and led multiple commercial teams, notably serving on the executive team at neuromodulation company Advanced Bionics. Boston Scientific acquired Advanced Bionics in 2004.

Surek 曾在五家医疗设备公司的商业成功中发挥了重要作用，这些公司成功实现了并购退出。他组建并领导了多个商业团队，尤其值得一提的是，他曾担任神经调节公司 Advanced Bionics 的执行团队成员。2004年，Boston Scientific 收购了 Advanced Bionics。

Surek also led the sales organization at Entellus Medical, which .

Surek还领导了Entellus Medical的销售组织，。

Stryker acquired in 2018

史赛克于2018年收购

.

。

Valencia expects Surek to accelerate commercial adoption for eCoin and position the company for its next stage of growth.

瓦伦西亚预计Surek将加速eCoin的商业应用，并为公司下一阶段的增长做好准备。

“I am excited to return to the neuromodulation space,” said Surek. “Many physicians and patients have already experienced the benefits of Valencia’s game-changing technology. We are looking forward to expanding our footprint in the market to bring our solution to those who want or require another option.”.

“我非常兴奋能够回归神经调节领域，”Surek说道。“许多医生和患者已经体验到了瓦伦西亚变革性技术带来的好处。我们期待扩大在市场中的影响力，将我们的解决方案带给那些希望或需要另一种选择的人。”

Brooks Advisory Group, a BMG affiliate, funded the company’s $35 million round. BMG also intends to provide consulting services for Valencia and eCoin.

布鲁克斯咨询集团（Brooks Advisory Group），作为BMG的附属机构，为该公司的3500万美元融资提供了资金。BMG还计划为瓦伦西亚（Valencia）和eCoin提供咨询服务。